Health ❯ Healthcare ❯ Pharmaceuticals ❯ Cancer Treatment

Multiple Myeloma

Tecvayli Cuts Progression Risk 71% and Deaths 40% in Phase 3 Myeloma Trial

Regulatory discussions are planned following independent confirmation of benefit.

FDA Reapproves GSK’s Blenrep for Multiple Myeloma in Narrow Combination Use

J&J Myeloma Trial Stopped Early After Tecvayli–Darzalex Shows PFS and OS Benefit